A Demure Teenager and Her Dystonic Foot
Neurol 89:e71-e75, Cullinane, P.W.,et al, 2017
Changing Gears - DBS for Dopaminergic Desensitization in Parkinsons Disease?
Ann Neurol 90:699-710, Weiss, D.,et al, 2021
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Tai Chi and Postural Stability in Patients with Parkinsons Disease
NEJM 366:511-519, Li,F.,et al, 2012
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Cycling for Freezing of Gait
NEJM 362:e46, Snijders,A.H., &Bloem,B.R., 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Botulinum Toxin for Cricopharyngeal Dysfunction in Parkinson's Disease
NEJM 346:1174-1175, Restivo,D.A.,et al, 2002
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998
Double-Blind Evaluation of Subthalamic Nucleus Deep Brain Stimulation in Advanced Parkinson's Disease
Neurol 51:850-855, Kumar,R.,et al, 1998
Motor, Cognitive, and Behavioral Performance Following Unilateral Ventroposterior Pallidotomy for Parkinson Disease
Arch Neurol 55:1201-1208, Masterman,D.,et al, 1998
Multiple System Atrophy presenting as Parkinsonism:Clinical Features and Diagnostic Criteria
JNNP 59:144-151, Albanese,A.,et al, 1995
Physical Therapy and Parkinson's Disease:A Controlled Clinical Trial
Neurol 44:376-378, Comella,C.L.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Drug-Induced Alzheimerism
Arch Neurol 45:356-357, Kurlan,R.&Como,P., 1988
Neuropsychological Effects of Brain Autograft of Adrenal Medullary Tissue for Treatment of Parkinson's Disease
Neurol 38:1442-1450, Ostrosky-Solis,F.,et al, 1988
Role of Subcutaneous Apomorphine in Parkinsonian Voiding Dysfunction
Lancet 2:1451-1453, Christmas,T.J.,et al, 1988
Drug Therapy, Bromocriptine
NEJM 301:873-878, Parkes,D., 1979
Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020
Deep Brain Stimulation in Early-Stage Parkinson Disease
Neurol 95:e393-e401,e431, Hacker, M.L.,et al, 2020
Non-Motor Symptoms in Parkinsons Disease are Reduced by Nabilone
Ann Neurol 88:712-722, Peball, M.,et al, 2020
Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinsons Disease
NEJM 383:2501-2513,2582, Martinez-Fernandez, R.,et al, 2020
When to Start Levodopa Therapy for Parkinsons Disease
NEJM 380:389-390, Bressman, S. & Saunders-Pullman, R., 2019
The Laser Shoes
Neurol 90:e164-e171, Barthel, C.,et al, 2018
National Randomized Controlled Trial of Virtual House Calls for Parkinson Disease
Neurol 89:1152-1161,1103, Beck, C.A.,et al, 2017
Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017
Cystic Lesions as a Rare Complication of Deep Brain Stimulation
Mov Disord Clin Pract 3:87-90, Sharma, V.D.,et al, 2016
Long-Term Clinical Outcomes After Fetal Cell Transplantation in Parkinson Disease Implications for the Future of Cell Therapy
JAMA 311:617-618, Bega, D. & Krainc, D., 2014
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014
Randomized Controlled Clinical Trial of "Virtual House Calls" for Parkinson Disease
JAMA Neurol 70:565-570, Dorsey, E.R.,et al, 2013
Caffeine for Treatment of Parkinson Disease
Neurol 79:651-658, Postuma, R.B.,et al, 2012
Deep Brain Stimulation
JAMA 305:732, Pluta,R.,et al, 2011
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Extended-Release Pramipexole in Advanced Parkinson Disease
Neurol 77:767-774, Schapira, A.H.V.,et al, 2011
Pallidal Versus Subthalamic Deep-Brain Stimulation for Parkinsons Disease
NEJM 362:2077-2091, Pollett,K.A., et al, 2010
Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients with Advanced Parkinson Disease: A Randomized Controlled Trial
JAMA 301:63-73,104, Weaver,F.M.,et al, 2009
Overweight After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson Disease: Long Term Follow-Up
JNNP 80:484-488, Bannier,S.,et al, 2009